Evidence map›Paper›PMID 29649654›Full record

ArticlePapillomavirus research (Amsterdam, Netherlands)2018

HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer.

Sérgio Menezes Amaro-Filho, Cláudia Bessa Pereira Chaves, Shayany Pinto Felix, Diogo Lisbôa Basto, Liz Maria de Almeida, Miguel Angelo Martins Moreira

Open access · goldAbstract readComparative Study
In one paragraph

Article in Papillomavirus research (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Disruption Events in the HPV18International journal of molecular sciences · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Designing of CD8Biologics : targets & therapy · 2018
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sérgio Menezes Amaro-FilhoGenetics Program, Instituto Nacional de Câncer (INCA), Andre Cavalcanti 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: sergioafilho@gmail.com.
Cláudia Bessa Pereira ChavesGynecologic Section and Molecular Carcinogenesis Program, Instituto Nacional de Câncer (INCA), Brazil. Electronic address: claudia.bessa67@gmail.com.
Shayany Pinto FelixGenetics Program, Instituto Nacional de Câncer (INCA), Andre Cavalcanti 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: shayany_shay@yahoo.com.br.
Diogo Lisbôa BastoGenetics Program, Instituto Nacional de Câncer (INCA), Andre Cavalcanti 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: diogolb89@gmail.com.
Liz Maria de AlmeidaDivision of Population Research - Instituto Nacional de Câncer (INCA), Brazil. Electronic address: lalmeida@inca.gov.br.
Miguel Angelo Martins MoreiraGenetics Program, Instituto Nacional de Câncer (INCA), Andre Cavalcanti 37, Rio de Janeiro, RJ 20231-050, Brazil. Electronic address: miguelm@inca.gov.br.
Instituto Nacional do Câncer · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare and describe type-specific characteristics of HPV16, HPV18 and HPV45 in cervical cancer with respect to 3'LCR methylation and disruption of E1/E2.

methodsThe methylation level of 137 cervical cancer samples (70 with HPV16, 37 with HPV18, and 30 with HPV45) of Brazilian patients was analyzed by pyrosequencing. PCR amplifications were performed to characterize E1 and E2 disruption as an episomal surrogate.

resultsThe 3'LCR of HPV16 showed a higher methylation at all CpG sites (7%, 9%, 11%, 10% and 10%) than homologous HPV18 regions (4%, 5%. 6%, 9% and 5%) and HPV45 regions (7%, 7% and 5%). Presence of intact E1/E2 was associated with higher HPV16 and HPV18 methylation levels at all CpG sites (p < 0.05). Disruption of E1/E2 was more frequently found in HPV45 (97%) and HPV18 (84%) than in HPV16 DNA (30%). HPV16 disruption was more frequently found in E1 (48%) unlike HPV18, where it was found in E2 (61%). Concomitant disruption of E1/E2 was most frequent in HPV45 (72%).

conclusionsThe findings showed a higher methylation associated with intact E1/E2 for HPV16 and HPV18. The closely phylogenetic related HPV18 and HPV45 share a similar methylation level and the frequency of viral genome disruption.

Indexed as

DNA MethylationAdultBrazilDNA-Binding ProteinsFemaleGenome, ViralHigh-Throughput Nucleotide SequencingHuman papillomavirus 16Human papillomavirus 18HumansMiddle AgedOncogene Proteins, ViralPapillomaviridaePapillomavirus InfectionsPhylogenyPromoter Regions, GeneticDNA-Binding ProteinsE1 protein, Human papillomavirus 16E2 protein, Human papillomavirus type 16oncogene protein E1, Human papillomavirus type 18oncogene protein E2, Human papillomavirus type 18Oncogene Proteins, ViralHPV genomeHuman papillomavirusInvasive cervical cancerMethylationPyrosequencingViral genome integration

Identifiers

PMID29649654
PMCPMC6046686
OpenAlexW2796811752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.